[HTML] nih.gov

[HTML][HTML] Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - ncbi.nlm.nih.gov
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often
suboptimal. Individualized combinations are needed in order to attenuate resistance. To …
被引用次数：52 相关文章

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - escholarship.org
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often
suboptimal. Individualized combinations are needed in order to attenuate resistance. To …

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - pubmed.ncbi.nlm.nih.gov
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often
suboptimal. Individualized combinations are needed in order to attenuate resistance. To …

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - europepmc.org
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often
suboptimal. Individualized combinations are needed in order to attenuate resistance. To …
[HTML] oncotarget.com

[HTML][HTML] Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - oncotarget.com
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often
suboptimal. Individualized combinations are needed in order to attenuate resistance. To …

[引用][C] Dosingde novocombinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - cir.nii.ac.jp
Dosing<i>de novo</i>combinations of two targeted drugs: Towards a customized precision
medicine approach to advanced cancers | CiNii Research CiNii 国立情報学研究所 学術情報 …

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

S Liu, M Nikanjam, R Kurzrock - Oncotarget, 2016 - oncotarget.com
Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often
suboptimal. Individualized combinations are needed in order to attenuate resistance. To …